By Connor Hart

Shares of Kiniksa Pharmaceuticals International jumped after the company swung to a profit in the second quarter, boosted by accelerating adoption of its treatments.

The stock climbed 14%, to $30.96, in premarket trading Tuesday. Through Monday's close, shares have edged 2.1% higher over the past year.

Before the bell, the biopharmaceutical posted a profit of $17.8 million, compared with a loss of $3.9 million a year earlier. Quarterly earnings came in at 23 cents a share, just ahead of the 22 cents a share that analysts polled by FactSet expected.

Revenue jumped 44% to $156.8 million and topped the $146.5 million that Wall Street modeled.

Under its current operating plan, Kiniksa said it expects to remain cash flow positive on an annual basis. The company additionally raised its net sales forecast for Arcalyst to between $625 million and $640 million from between $590 and $605 million.

Arcalyst is the company's treatment for recurrent pericarditis, a condition in which the membrane that surrounds the heart becomes inflamed, causing sharp chest pains.

"Our robust commercial performance in the second quarter was driven by expanding Arcalyst penetration across the recurrent pericarditis population, supported by growth among both new and repeat prescribers," Chief Executive Sanj Patel said.

The company noted that it is recruiting patients for a Phase 2/3 clinical trial of another treatment for recurrent pericarditis. It expects to release data from the study in the second half of next year, targeting a potential market entry by 2029.

Write to Connor Hart at connor.hart@wsj.com

(END) Dow Jones Newswires

July 29, 2025 09:07 ET (13:07 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.